Christopher Shilling News Today

Researchers want to streamline the drug development process to reduce costs and enable companies to bring more gene therapies to patients.

Forge Biologics has received PRIME designation from the EMA for its drug candidate FBX-101 to treat patients with Krabbe disease.

FBX-101 is granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) after review of Phase 1/2 RESKUE clinical trial safety and efficacy data PRIME designation